Treace Medical Shareholders Back Directors, Pay and Auditor

Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in secondsTreace Medical Concepts ( (TMCI) ) has shared an update. At its annual meeting of stockholders held on May 19, 2026, Treace Medical Concepts, Inc. shareholders elected Class II directors Lance A. Berry, Elizabeth S. Hanna and Jane E. Kiernan to three-year terms ending with the 2029 annual meeting. The voting results reaffirmed the existing board structure and suggest continued support for the company’s current strategic direction. Stockholders also approved, on an advisory and non-binding basis, the executive compensation program for the company’s named executive officers, indicating broad investor backing of management’s pay practices. In addition, shareholders ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing continuity in the company’s financial oversight and audit framework. The most recent analyst rating on (TMCI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page. Spark’s Take on TMCI Stock According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral. The score is primarily held back by weak financial performance—ongoing losses and negative free cash flow—despite strong gross margins and some improvement in cash burn. Technicals are supportive short-term but appear overbought and still below the 200-day trend. Valuation offers limited support due to negative earnings, while the latest guidance indicates continued near-term revenue pressure alongside efforts to reduce cash usage. To see Spark’s full report on TMCI stock, click here. More about Treace Medical Concepts Treace Medical Concepts, Inc., a medical device company, develops and markets surgical solutions for foot and ankle conditions, with a particular focus on bunion correction procedures. The company targets orthopedic surgeons and podiatrists, positioning itself in the specialized orthopedic and podiatric surgery market within the broader medical technology industry. Average Trading Volume: 857,905 Technical Sentiment Signal: Sell Current Market Cap: $178.4M